Inventiva ($IVA) Stock Hub 2026: NATiV3 Completed Its Last Patient Visit, Lanifibranor Topline Confirmed For Q4 2026, And The Financing Was Built For That Date

01 Executive summary

Inventiva is a French clinical-stage company with one asset and one question. The asset is lanifibranor, an oral pan-PPAR agonist; the question is whether NATiV3, a 1,009-patient Phase 3 in metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis, reproduces at 72 weeks what a 247-patient Phase 2b showed at 24. On September 2, 2026 the company said the last patient had completed the last 72-week visit. That is not a result. It is the moment the double-blind database can close, and it turns a readout the company has guided to the fourth quarter of 2026 since March into an event with a fixed amount of work between here and there.

The financial structure is unusual because it was built for this date. In June 2026 Inventiva sold 27,272,727 ADSs at $4.40 for about $110.8M net, repaid the European Investment Bank in full, bought back the most dilutive EIB warrants for €50M, and issued €75M of senior secured bonds to funds managed by BlackRock and Claret Capital Partners that mature in April 2030. The bonds carry an event of default if the NATiV3 primary composite endpoint is missed. A further €55M Tranche C and up to €116M from the Tranche 3 warrants of the October 2024 structured financing are available only on positive data. So the company’s stated runway has two versions: to the end of the second quarter of 2027 on what it has, and to the start of the first quarter of 2028 if the readout is good and both conditional sources are used.

02 Market data and the share base behind it

Inventiva has two listings of the same share: ordinary shares on compartment B of Euronext Paris, ISIN FR0013233012, and American Depositary Shares on the Nasdaq Global Market, each ADS representing one ordinary share. The U.S. line has grown in weight with each transaction: 44,805,193 ADSs were sold in November 2025 at $3.85 and 27,272,727 in June 2026 at $4.40, and the company’s at-the-market programme with Piper Sandler, for up to $100M of ADSs under a $300M shelf filed in October 2025, is a Nasdaq instrument. The figures below state the base they use.

Two observations follow from the table rather than from opinion. First, the market capitalisation on issued shares excludes the pre-funded warrants sold in the 2024 and 2025 structured-financing tranches, which have an exercise price of €0.01 and behave like shares; the lenders’ own debt-to-capitalisation covenant explicitly counts them. Second, Finviz’s float of 218.37M and the company’s 130.0M differ because the vendor subtracts only what it classifies as insider holdings, while the company subtracts every disclosed holder above roughly 4%. Neither is wrong; they measure different things, and each figure above states which one it uses.

03 Verified developments, June to September 2026

Each item below is dated from the primary document, not from the day it was reported by an aggregator.

June 2, 2026 — Trading in Paris was halted at the company’s request from 9:00 a.m. CEST and resumed at 3:30 p.m. after the announcement of the combined transaction: a $120M underwritten offering of 27,272,727 ADSs at $4.40 in the United States only, a debt financing of up to €130M in committed tranches plus €20M uncommitted with BlackRock and Claret Capital Partners, and an agreement with the EIB to repay the loan early and repurchase warrants. Andera Partners subscribed for 1,815,000 shares and Samsara for 1,120,000. Leerink Partners and Stifel were joint bookrunners.

June 5, 2026 — Settlement of the equity offering, for net proceeds of approximately $110.8M (€95.2M).

June 12, 2026 — The EIB loans were prepaid in full for €62,204,435.60 including accrued interest, with the EIB waiving its prepayment fees. All 2,266,023 Tranche A warrants and 700,000 Tranche B warrants, together representing about 22.7 million underlying shares after the anti-dilution adjustments, were repurchased and cancelled for €50M. The same day the company issued Tranche A, €35M of convertible bonds, and Tranche B, €40M of amortising bonds, for net proceeds of €71,298,750, plus 1,624,196 lender warrants at €4.1559 and 661,709 more that only become exercisable if Tranche C is drawn.

June 30, 2026 — The combined general meeting adopted all resolutions except the 31st (an employee savings-plan capital increase that the board itself had recommended against), on a quorum of 71.874%. Three new directors were elected: Camilla Soenderby, Anne Prener and Barbara Krebs-Pohl. The pay resolutions passed with roughly 80% in favour, which is a visible minority dissent on compensation after a year in which general and administrative expenses included €20.3M of share-based charges tied to the management transition.

July 9, 2026 — 15,677,573 new EIB warrants were issued at €0.01 with an exercise price of €0.01, exercisable from August 30, 2026 to January 4, 2036, in substitution for the 2,444,654 remaining legacy Tranche B warrants, which were cancelled. The new instrument has no anti-dilution ratchet and no put option. The company published its share register: 236,280,202 shares non-diluted, 433,608,437 fully diluted.

July 29 and 30, 2026 — Preliminary first-half figures, then a correction. Cash and cash equivalents of €166.1M and short-term deposits of €67.8M at June 30; net cash used in operations of €48.7M; R&D of €50.1M; no revenue. The correction changed the stated size of Tranche C from €20M to €55M and nothing else.

August 30, 2026 — The new EIB warrants became exercisable. No exercise has been disclosed as of September 3, 2026.

August 31, 2026 — Chris Benecchi appointed Chief Operating Officer. The company describes his mandate as building the organisation and capabilities for a potential launch.

September 2, 2026 — Last patient, last visit in NATiV3. Half-year results moved to Monday September 28, 2026, with the call at 8:00 a.m. New York and 2:00 p.m. Paris. September conference schedule published.

04 Lanifibranor: the mechanism and the Phase 2b it rests on

Lanifibranor activates all three peroxisome proliferator-activated receptor isoforms, alpha, delta and gamma, with what the company describes as a moderately potent, balanced profile: full activation of PPAR-alpha and PPAR-delta and partial activation of PPAR-gamma. The rationale for going after all three at once is that MASH is a metabolic, inflammatory and fibrotic disease together, and the isoforms sit on different parts of that circuit: alpha on fatty-acid oxidation in the liver, delta on inflammation and macrophage biology, gamma on adipose tissue and insulin sensitivity. Earlier single- and dual-agonist attempts in the class, including pioglitazone off-label and elafibranor, either carried gamma-class side effects or missed on histology. Inventiva’s bet is that partial gamma activation keeps the metabolic benefit while blunting the weight gain and fluid retention of full agonists. The company states that lanifibranor is the only pan-PPAR agonist in clinical development for MASH, and the 20-F lists Breakthrough Therapy Designation granted in October 2020 and Fast Track designation, extended in September 2021 to MASH with compensated cirrhosis.

NATIVE, the Phase 2b published in the New England Journal of Medicine

NATIVE randomised 247 patients with non-cirrhotic, highly active MASH 1:1:1 to 1,200 mg, 800 mg or placebo once daily for 24 weeks; 42% had type 2 diabetes and 76% had significant or advanced fibrosis. The primary endpoint was a decrease of at least two points in the SAF-A activity score without worsening of fibrosis. The published results, from Francque et al., October 21, 2021:

The 800 mg dose did not reach significance on the primary endpoint; the 1,200 mg dose did. The paper reports that liver enzymes fell and most lipid, inflammatory and fibrosis biomarkers improved on drug, that dropouts for adverse events were below 5% and similar across arms, and that diarrhoea, nausea, peripheral oedema, anaemia and weight gain were more frequent with lanifibranor than with placebo. Those last three are the PPAR-gamma signature, and they are the reason the 72-week safety profile of NATiV3 matters as much as its efficacy.

Since NATIVE the company has published several supporting analyses: a proof-of-concept investigator-initiated trial in patients with type 2 diabetes and MASLD in the Journal of Hepatology in January 2025, a preclinical portal-hypertension study in February 2025, a non-invasive signature predictive of histological response in Clinical Gastroenterology and Hepatology in April 2025, and work on liver sinusoidal endothelial cells in JHEP Reports in July 2025. A clinical QT/QTc study in 217 healthy volunteers, announced in December 2021, found no effect on cardiac repolarisation. None of these substitutes for the Phase 3.

05 NATiV3: design, endpoints, and what the last patient visit does and does not mean

NATiV3 (NCT04849728) is a randomised, double-blind, placebo-controlled, multicentre Phase 3 that started on August 19, 2021 and lists 459 sites across 24 countries on ClinicalTrials.gov, including the United States, most of Western and Eastern Europe, Brazil, Argentina, Mexico, China, Australia and South Africa. The main cohort enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and fibrosis stage F2 or F3, randomised to lanifibranor 800 mg (two 400 mg tablets plus one placebo), 1,200 mg (three tablets) or matching placebo, once daily with food, for 72 weeks. Part B is a 48-week active-treatment extension in which every patient, including those who were on placebo, receives lanifibranor; it is designed to add long-term safety exposure, and it is listed in the registry as a second primary outcome, a safety analysis; the registry’s estimated primary completion and completion dates of September 30, 2027 include it, while the topline on the week-72 histology is the company’s Q4 2026 guidance.

The composite is the harder bar

The two approved MASH drugs were cleared under accelerated approval on histology, resmetirom at 52 weeks and semaglutide at 72, with either of two endpoints sufficient: MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH. NATiV3’s primary endpoint requires both in the same patient, at 72 weeks, which is a stricter test; in NATIVE the both-together rate was 35% on 1,200 mg against 9% on placebo. The company’s own instruments reflect the distinction: the Tranche 3 warrants become exercisable if any key primary or key secondary endpoint is met, and the lenders’ default clause has a cure path if specified key secondary endpoints are met even when the composite is not. A reader should therefore expect that the topline release will report the composite and the two components separately, and that the market will read all three.

The SUSAR of early 2024 and what it changed

In the first quarter of 2024, following a routine visit, a patient in NATiV3 was reported with elevated aminotransferases that were assessed as a treatment-related suspected unexpected serious adverse reaction, and other milder elevations were also reported. Inventiva voluntarily paused screening and randomisation and, with input from the FDA and on the recommendation of the Data Monitoring Committee, amended the entry criteria to exclude patients diagnosed with or predisposed to autoimmune liver or thyroid disease and increased the frequency of liver monitoring. Enrolment resumed and completed in April 2025. The 20-F is explicit that the company cannot assure the final impact of the SUSAR on the results, and that any significant safety finding could affect how regulators read the profile, up to a boxed warning if approved. It is the single most important piece of context for the safety half of the readout.

06 Regulatory path: what is dated and what is conditional

The regulatory calendar is entirely downstream of the readout, and the company has been consistent about its shape since the March 30, 2026 results release: topline in the fourth quarter of 2026; if positive, a New Drug Application submission in the first half of 2027; potential U.S. commercialisation in 2028, subject to FDA approval. The September 2 release repeats it word for word. No European filing timeline has been given beyond the general statement that a marketing authorisation application to the EMA would follow.

Three designations frame the file. Fast Track, granted before 2020 and extended in September 2021 to MASH with compensated cirrhosis, allows rolling submission and more frequent FDA contact. Breakthrough Therapy Designation, granted in October 2020 on the Phase 2b data, adds intensive guidance on the development programme and eligibility for priority review; it is not an approval and the FDA can rescind it. The company also holds Breakthrough-type status from China’s NMPA. Against that, the 20-F carries two warnings that belong in any reading of the path: the 2024 SUSAR could shape labelling up to a boxed warning, and the FDA’s guidance during a 2023 consultation was to continue the trial as originally planned rather than adopt certain protocol amendments the company had proposed, which is a reminder that the agency has its own view of this dataset.

A planned Phase 3 outcomes trial in MASH with compensated cirrhosis is mentioned in the 20-F as part of the programme, without a start date or a funding plan. That is the study that would turn an accelerated approval, if granted, into a full one.

07 The MASH market lanifibranor would enter

MASH, the progressive form of fatty liver disease with inflammation and fibrosis, went from no approved therapy to two in eighteen months. In March 2024 Madrigal received accelerated FDA approval for Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, for MASH with moderate to advanced fibrosis, and in August 2025 the European Commission granted it a conditional marketing authorisation. In August 2025 the FDA approved Novo Nordisk’s Wegovy (semaglutide) for MASH with moderate to advanced fibrosis, on the basis of a 72-week histology readout, and in November 2025 Novo announced positive post-hoc analyses from that programme. Both are facts the company itself states in its annual report as reasons its candidate faces competition and could reach the market later than rivals.

The commercial argument Inventiva makes is one of positioning rather than exclusivity: an oral, once-daily small molecule with a mechanism that touches metabolism, inflammation and fibrosis together, in a disease where a large fraction of patients are diabetic and where the incretin class is limited by tolerability, injection and cost, and the THR-beta class is limited to the liver. Whether that argument holds depends on numbers nobody has yet: the size of the effect on fibrosis at 72 weeks, the weight and fluid profile at that duration, and the price. The organisation is being built as if the answer were yes: a Chief Commercial Strategy Officer was hired in December 2025, marketing and business-development expense rose to €5.0M in 2025 from €2.0M, and a Chief Operating Officer with a launch background arrived on August 31, 2026.

Outside the United States and Europe the asset is already partnered: Chia Tai Tianqing holds Greater China rights, and Hepalys Pharma, a company formed with Catalys Pacific in September 2023, holds Japan and South Korea and began a clinical programme in Japan in February 2025. Those arrangements are set out in section 11.

08 Financials: 2025 accounts and the preliminary 2026 half

Inventiva reports under IFRS in euros. The 2025 income statement below is as filed on March 30, 2026 and in the 20-F; the figures are not converted, because a converted P&L would mix three exchange rates. The headline conversions in the At a glance panel state their rate.

Three lines explain the year. Research and development fell 4% to €87.0M as the company stopped all preclinical work under its 2025 pipeline prioritisation plan, which terminated the YAP-TEAD and NR4A1 programmes and cut the workforce by about half, to 77 employees at December 31, 2025, sixty in France and seventeen in the U.S. subsidiary. General and administrative expense tripled to €47.9M, of which €20.3M was share-based compensation linked to the change of management and the accelerated vesting of awards. And the net financial loss of €212.8M was overwhelmingly non-cash: €84.7M of fair-value loss on the derivative instruments embedded in the second tranche of the structured financing and €95.1M on the EIB warrants, both of which rise when the share price rises, plus €28.9M of mostly non-cash interest on loans and royalty certificates. The net loss attributable to shareholders equals the total because there is no minority interest. Revenue of €4.5M was the $10M CTTQ milestone invoiced on the second structured-financing tranche, net of the $5M of credit notes recognised under the same licence; nothing in 2026 so far.

The first half of 2026, preliminary

The July 29 release gives cash flows, not a P&L. Net cash used in operations was €48.7M against €53.7M a year earlier, the improvement coming from an €8.8M working-capital swing that partly offset higher trial and pre-commercial spending; R&D was €50.1M against €44.9M. Investing generated €63.9M as deposits were unwound and re-subscribed around the June transactions. Financing generated €50.9M net, which the company attributes to the €103M equity offering and the €75M of bonds, offset by the €62.2M EIB repayment and the €50M warrant repurchase, after fees and the other financing lines the half-year report will itemise. The full half-year report, with the income statement, the balance sheet and the going-concern note, is due on September 28, 2026.

The going-concern language is worth quoting exactly, because it is easy to misread in both directions. The company expects to be able to finance its operations as currently planned until the end of the second quarter of 2027, and states that at the date of the release its current cash and cash equivalents are not sufficient to cover operating needs as currently planned for the next twelve months. Those two sentences are consistent: twelve months from July 29, 2026 reaches past the end of Q2 2027. The 2025 audit report carried a material-uncertainty paragraph for the same reason. The extension to the start of Q1 2028 requires Tranche C and the full exercise of the Tranche 3 warrants, and both require the readout to go the company’s way.

09 The June 2026 refinancing, instrument by instrument

The combined transaction of June 2026 replaced a €50M EIB loan due in December 2026 and January 2027, and the warrants attached to it, with a longer, larger and more expensive facility whose terms are indexed to the readout. It also removed an open dispute: the EIB warrants carried anti-dilution ratchets that had inflated their underlying share count from 5.4 million to a company estimate of 22.7 million and, on the EIB’s own calculation, 38.4 million, with the exercise ratio “under discussion” in the 20-F. Paying €50M to cancel 60% of that exposure, at what the company calls a 40% discount to intrinsic value at the offering price, and swapping the rest into 15.7 million plain warrants, is the part of the deal that changed the share structure most.

Two mechanics deserve a plain reading. First, the default clause: missing the primary composite endpoint is an event of default on Tranches A and B, curable if specified key secondary endpoints are met and the T3 warrants are exercised in cash within the cure period, during which the company must keep cash equal to 100% of the bonds outstanding in Luxembourg accounts. If the bonds outstanding exceed 10% of post-results market capitalisation, the holders can require a prepayment down to the greater of €50.0M and that 10%; once the warrants are exercised in a cure, a mandatory prepayment takes the bonds to no more than 7.5% of post-cure capitalisation, and below €400M of post-cure capitalisation the holders can require full repayment. Second, the cost: on €75M the cash coupon alone is about €7.4M a year before PIK, against a half-year operating cash use of €48.7M, so the debt adds roughly 7% to the annual burn for as long as it is outstanding.

10 The dilution map: every instrument that can become a share

This is where the share count and the readout meet. The company’s July 9 table gives 236,280,202 shares non-diluted and 433,608,437 fully diluted, an 83.5% difference. The instruments behind the gap are listed below with what triggers each one. The pre-funded warrant balance is the one line the company has not stated as a single current figure; the issuance history is given instead.

Read together, the table says something specific about the readout. A positive result would be followed, within months, by up to 77.3 million new shares from the T3 warrants at about €1.50, a price far below the June 2026 offering price of €3.7781, because those warrants were priced in May 2025 as the deferred third tranche of a rescue financing. That is the cost of the 2024 structured financing coming due, and it is dilution that arrives precisely when the equity is strongest. A negative result removes it, along with Tranche C, and leaves the company with its existing cash, €75M of bonds in default and a share register that would then be diluted by whatever came next. The 20-F’s own estimate, before the June transactions, was that exercising every instrument would dilute holders by about 48%; the July fully-diluted count implies more, because the June deal added the convertible, the lender warrants and the plain EIB warrants while removing the ratcheting ones.

11 Partnerships, licences and what was sold

Chia Tai Tianqing (CTTQ), Greater China. The licence, signed in September 2022 and amended on October 11, 2024 alongside the structured financing, gives CTTQ sole responsibility for commercialisation in its territory. The original terms provided up to $40M of development and regulatory milestones, up to $250M of commercial milestones and tiered royalties from high single digits to mid-teens; the October 2024 amendment added three $10M milestones, the first triggered by the October 2024 financing closing and paid, the second by the May 2025 closing and paid, and the third by the publication of positive topline data from NATiV3, which makes CTTQ a $10M line item on the readout; it also removed two $10M development milestones and reduced the royalty in the territory to a flat low single-digit rate. CTTQ could either join NATiV3 or run its own study; Chinese sites appear in the NATiV3 registry. The 2025 revenue of €4.5M and the 2024 revenue of €9.2M were both CTTQ money.

Hepalys Pharma, Japan and South Korea. On September 20, 2023 Inventiva granted an exclusive licence to Hepalys Pharma, Inc., a company formed with Catalys Pacific Fund II, under a shareholders’ agreement that gives Inventiva an equity stake accounted for by the equity method (a €0.35M share of loss in 2025). Hepalys began the clinical development programme in Japan in February 2025. Milestone and royalty terms are in the 20-F exhibits and are not summarised in the results releases.

Odiparcil, sold. In 2025 the company sold its global rights to odiparcil, a Phase 2a asset in mucopolysaccharidosis type IV, to Biossil, Inc. for $600,000 up front, up to $90M of regulatory and commercial milestones and high single-digit royalties if approved. The company is explicit that it has no control over whether any of that is ever paid.

Royalty certificates. In 2023 and July 2024 Inventiva raised money by selling royalty certificates entitling holders to 2% and 3% respectively of annual net sales of lanifibranor until 2038 in the first of the United States, the European Union or the United Kingdom to see a launch. They cost the company nothing unless the drug sells, and then they cost 5% of sales for a decade.

What the company does not have is a Western commercial partner. The June 2 release says the debt maturity extension reflects lender confidence; it does not mention a partnering process, and the forward-looking statements list the ability to cooperate with existing partners or enter new ones as a risk rather than a plan. A go-it-alone U.S. launch in 2028 with 77 employees at the last count is the plan on paper, and the COO hire is the first visible step of it.

12 Management, board and governance

The executive team was almost entirely rebuilt between mid-2025 and August 2026. Andrew Obenshain, previously President and Chief Executive Officer of bluebird bio from November 2021 until its June 2025 acquisition, became Chief Executive Officer on October 1, 2025, succeeding co-founder Frédéric Cren, who had run the company since it acquired lanifibranor from Abbott in 2012 and who retains 5,878,891 shares. Co-founder Pierre Broqua stepped down as Deputy CEO on June 30, 2025 and holds 3,769,388 shares with double voting rights. Around the CEO: Axel-Sven Malkomes as Chief Financial Officer; Jason Campagna, M.D., Ph.D., President of Research and Development and Chief Medical Officer since July 2025; Martine Zimmermann, PharmD, Executive Vice President of Regulatory Affairs and Quality Assurance since August 2025; Nazira Arma, Chief Commercial Strategy Officer since December 2025; and Chris Benecchi, Chief Operating Officer since August 31, 2026, with launch experience from Sage Therapeutics (ZURZUVAE), UCB (BIMZELX) and Alexion. Mark Pruzanski, chairman since December 2024, was a co-founder and director of Intercept Pharmaceuticals and Chief Executive Officer of Versanis Bio until its 2023 acquisition by Eli Lilly; Dr. Campagna was Intercept’s Global NASH Lead and later its Chief Medical Officer, which puts two people with obeticholic-acid history at the top of the company.

The June 30, 2026 meeting renewed Renée Aguiar-Lucander and Heinz Maeusli and added Camilla Soenderby, Anne Prener and Barbara Krebs-Pohl. Every resolution passed except the employee savings-plan one that the board had opposed; the compensation resolutions for the chairman, the former and current CEO and the former deputy CEO each drew about 20% against, and the authorisations to issue shares without pre-emptive rights, including the ATM authorisation, drew about 19% against. The lenders are entitled to appoint non-voting observers to the board under the June financing.

The governance facts that matter for a reader are three. The company follows French law rather than Nasdaq Rule 5635 on shareholder approval of share issuances, which is why it could issue 27.3 million ADSs in June under an existing delegation. The 2025 accounts absorbed €20.3M of share-based charges from the transition, so the cost of the new team was front-loaded. And the people who will present the Phase 3 result were, with the exception of the CFO and the chairman, not in their seats when the trial was designed or when the 2024 safety pause was handled; that cuts both ways and is simply a fact of the record.

13 Retail sentiment

Retail positioning is not a fundamental input, but on a stock whose next event is binary it says something about who is holding it into the date. The Stocktwits reading of September 3, 2026 shows a modest, bullish-leaning audience: a normalised sentiment score of 60 out of 100, labelled bullish by the platform, on a message-volume score of 37 out of 100, labelled low, with 670 watchers. Message volume over the past year is about double the platform’s baseline for the symbol, which fits a name that has come onto U.S. radar through two Nasdaq offerings.

The recurring themes in the stream are three. A countdown framing: posts noting that the fourth-quarter window opens on October 1 and treating the last patient visit as the starting gun. A partnership narrative: the expectation that positive data would draw a licensing or acquisition offer, for which there is no company statement. And cost benchmarking: at least one long post uses Inventiva’s disclosed lanifibranor spending since 2021 as a reference for what a biopsy-driven MASH Phase 3 costs, which is a legitimate use of the filings. There is little bearish argument in the stream and almost no discussion of the default clause in the June bonds or of the €1.50 Tranche 3 warrants, which is the kind of gap between the retail conversation and the documents that a hub like this one exists to close.

14 Catalyst table

Every item marked conditional depends on the fourth-quarter readout. That is the shape of the year: one event, and a calendar of contractual consequences arranged on either side of it.

15 The constructive case

The Phase 3 is the largest histology-based trial in the class and it is finished treating. 1,009 patients in the main cohort, two doses, 72 weeks, biopsy at both ends, at 459 sites. There is no enrolment risk, no retention risk and no protocol risk left; what remains is analysis. The company has held the fourth-quarter window since it first gave it in March 2026, through a management change and a refinancing.

The Phase 2b was strong on exactly the endpoints regulators use. At 24 weeks and 1,200 mg, MASH resolution without worsening of fibrosis in 49% of patients against 22% on placebo, fibrosis improvement of at least one stage in 48% against 29%, and both together in 35% against 9%, in a peer-reviewed New England Journal of Medicine publication. Two drugs have since been approved on those two endpoints, which settles the question of whether the FDA accepts histology at this stage of disease.

The mechanism is differentiated, and the company is the only one running it. A single oral pill acting on metabolism, inflammation and fibrosis at once, in a disease where the approved options are a liver-selective thyroid agonist and an injectable incretin. If the fibrosis effect at 72 weeks is in the range NATIVE suggested, lanifibranor would have a claim to the patient who does not want, tolerate or afford an injection, and to combination use.

The balance sheet was rebuilt before the readout, not after. €233.9M of cash and deposits at June 30, 2026 against a half-year cash use of €48.7M; no debt maturity before April 2030; the ratcheting EIB warrants gone; a Nasdaq listing with 72 million ADSs sold to U.S. institutions in seven months, including Andera and Samsara buying more in June. On a positive result the company can call on €55M of Tranche C, up to €116M from the T3 warrants and $10M from CTTQ without going back to the market.

The organisation now has a launch team. A CEO who ran bluebird bio through two gene-therapy launches, a CMO who led the NASH programme at Intercept, a regulatory head, a commercial strategy officer and, since August 31, a COO who ran launch readiness at Sage and UCB. Whatever one thinks of the odds, the company is not improvising the 2027-2028 plan.

16 The sceptical case

Nobody has seen the data, and the composite is a harder bar than the approved drugs cleared. NATiV3 requires MASH resolution and fibrosis improvement in the same patient at 72 weeks. Phase 2b response rates over 24 weeks in a highly active population do not translate mechanically to 72 weeks in F2/F3 patients, placebo response in MASH trials has been high and variable, and every large MASH Phase 3 of the last decade with a novel mechanism, other than the two that succeeded, failed on histology.

The safety half of the readout has a documented open question. A treatment-related SUSAR of elevated liver enzymes in early 2024 paused the trial and changed the entry criteria; weight gain, oedema and anaemia were more frequent on drug in Phase 2b. Seventy-two weeks on a PPAR-gamma partial agonist is where those signals would show if they are going to, and a label with a liver-monitoring requirement or a boxed warning, the possibilities the 20-F itself names, would change the commercial case even with positive efficacy.

The financing makes a miss more expensive than a miss. Failure on the primary composite is an event of default on €75M of secured bonds unless key secondaries are met and €100M-plus of T3 warrants are exercised in cash within the cure period, with 100% cash cover required meanwhile and full repayment demandable if the post-cure capitalisation is below €400M. Tranche C disappears. The T3 warrants disappear. The company’s own runway without them ends in the second quarter of 2027, and it has said its cash does not cover twelve months of plan.

A hit brings its own dilution. Up to 77.3 million T3 shares at about €1.50, against 236.3 million issued and a June offering priced at €3.7781. The fully-diluted count is already 83.5% above the issued count. A positive readout would be followed by a period in which the share count rises fastest at the moment the price would be highest.

The market is no longer empty, and the company has no Western partner. Resmetirom has been on the U.S. market since 2024 and in Europe since 2025; semaglutide has a MASH label since August 2025; a 77-person company plans a U.S. launch in 2028 on its own, having listed the ability to find partners as a risk rather than a strategy. The CTTQ amendment already cut the China royalty to a flat low single digit and gave away two milestones in exchange for cash tied to the company’s own financings, which is what a company does when it needs the money more than the terms.

17 Scenario framework, not a forecast

These are analytical frames for reading the fourth quarter, not probabilities and not price targets.

18 Bottom line

On September 2, 2026 Inventiva moved NATiV3 from a trial in progress to a trial awaiting analysis. That is the last milestone that can be reached on schedule alone; everything after it depends on numbers that do not yet exist outside a locked database. The company arrives at the readout with €233.9M of cash and deposits at June 30, €75M of new secured debt maturing in 2030, a share count of 236.3M that becomes 433.6M fully diluted, a management team hired for a launch, and a set of contracts, from the T3 warrants to the CTTQ milestone to the bond default clause, that all read the same fourth-quarter result and pay or punish accordingly. The audited half-year on September 28 will fill in the balance sheet. The fourth quarter fills in everything else.

The facts above are dated and sourced; inferences are labelled as such. The Merlintrader Health Score below describes robustness over the next twelve to eighteen months and is not a view on the readout or on the shares.

Related Research On Merlintrader

• Top Ten Biotech Stocks Right Now — the biotech ranking and the entry point to every biotech hub.
• Merlintrader Stock Hubs — the complete map, sector by sector.
• Free Catalyst Calendar — every dated PDUFA, AdCom and readout in one place.
• Weekly Market Pulse — the weekly event calendar and market map.